Stock Financial Ratios, Dividends, Split History
CAG / ConAgra Foods, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.
|Market Cap ($M)||14,209.99|
|Enterprise Value ($M)||17,310.81|
|Book Value ($M)||3,720.50|
|Book Value / Share||9.45|
|Price / Book||3.77|
|NCAV / Share||-11.68|
|Price / NCAV||-3.06|
|Weighted Average Number Diluted Shares Outstanding Adjustment||4,100,000|
|Common Shares Outstanding||416,596,438|
|Weighted Average Number Of Shares Outstanding Basic||431,900,000|
|Preferred Stock Shares Outstanding||0|
|Weighted Average Number Of Diluted Shares Outstanding||436,000,000|
|Altman Z Score||N/A|
|Beneish M Score||N/A|
|Management Effectiveness (mra)|
|Return on Invested Capital (ROIC)||0.09|
|Return on Assets (ROA)||0.05|
|Return on Equity (ROE)||0.17|
|Identifiers and Descriptors|
|Central Index Key (CIK)||23217|
|SIC 20 - Food And Kindred Products|
Stock splits are used by ConAgra Foods, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
Related News Stories
In an attempt to simplify its portfolio, TreeHouse Foods, Inc. (THS - Free Report) concluded the sale of McCann's Irish Oatmeal brand to B&G Foods (BGS - Free Report) . The deal, which is expected to have an insignificant impact on TreeHouse Foods’ bottom line in 2018, is valued at nearly $32 million. Management plans to utilize the proceeds to repay debt. TreeHouse Foods added McCann's Irish Oatmeal under its umbrella in 2010, through its buyout of Sturm Foods. (3-0)
The consumer goods space can be a fickle one, with the industry largely dependent on economic trends and consumers’ disposable income and tastes. While that creates a challenging operating environment, it also offers investors a wide variety of potential turnaround stories to keep on their radar. (41-0)
Conagra (NYSE:CAG) released its earnings report for its fiscal fourth quarter of 2018 after the markets closed on Wednesday. (33-0)
Pinnacle Foods Inc. (NYSE: PF) shares dropped early on Wednesday after it was announced that the company would be acquired by Conagra Brands Inc. (NYSE: CAG). This will go down in a cash and stock deal valued at roughly $10.9 billion, including Pinnacle Foods’ outstanding net debt. The transaction is expected to close by the end of 2018. (33-0)
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Trade battles are set to dominate another week's action, with a set of hair-trigger responses from former trade allies leading world news though threatened tariffs are still small in the face of a $20T U. (1297-2)
as of ET